Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ

BACKGROUND: The treatment efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors like erlotinib has not met expectations for glioblastoma therapy, even for EGFR-overexpressing tumors. We determined possible mechanisms of therapy resistance using the unique BS153 glioblastoma...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Schulte, Alexander, Liffers, Katrin, Kathagen, Annegret, Riethdorf, Sabine, Zapf, Svenja, Merlo, Adrian, Kolbe, Katharina, Westphal, Manfred, Lamszus, Katrin
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2013
Materias:
Basic and Translational Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3779041/
https://ncbi.nlm.nih.gov/pubmed/23877316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not093
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares